Filing Flows › Standard Biotools (LAB) › Q3 2026 › vs Q2 2026
Standard Biotools (LAB) Q3 2026 vs Q2 2026 (quarter over quarter)
Standard Biotools's revenue fell $719K (-4%) from $20.1M in Q2 2026 to $19.4M in Q3 2026. The biggest changes: Services and Other Revenue −$532K (-10%); Product −$187K (-1%).
Standard Biotools, Q3 2026: revenue $19.4M (-0.9% year over year), operating margin -102.0%, net earnings $13.5M, operating cash flow −$6.2M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Consumables | $8.3M | $9.4M | −$1.1M | -11% |
| Instruments | $6.0M | $5.1M | $868K | +17% |
| Product | $14.3M | $14.5M | −$187K | -1% |
| Services and Other Revenue | $5.1M | $5.6M | −$532K | -10% |
| Revenue | $19.4M | $20.1M | −$719K | -4% |
| Other income, net | $33.3M | −$1.3M | $34.6M | — |
| Costs & expenses | $52.7M | $46.9M | $5.8M | +12% |
| Operating costs | $39.2M | $45.5M | −$6.3M | -14% |
| Income tax | $27K | $90K | −$63K | -70% |
| Net earnings | $13.5M | −$26.8M | $40.2M | — |
| Cost of revenue | $8.6M | $9.6M | −$1.0M | -11% |
| Research & development | $2.1M | $2.0M | $102K | +5% |
| SG&A | $16.8M | $16.4M | $455K | +3% |
| Other operating costs | $11.7M | $17.6M | −$5.9M | -34% |
| Operating cash sources | $24.6M | −$11.1M | $35.7M | — |
| Depreciation & amortization | $1.2M | $1.3M | −$70K | -5% |
| Share-based compensation | $3.7M | $4.0M | −$327K | -8% |
| Cash used in operations | $6.2M | $10.3M | −$4.2M | -40% |
| Working capital & other | $24.6M | −$11.1M | $35.7M | — |
Questions
How much did Standard Biotools's revenue grow quarter over quarter in Q3 2026?
Standard Biotools's revenue fell $719K (-4%) from $20.1M in Q2 2026 to $19.4M in Q3 2026.
What drove Standard Biotools's revenue change in Q3 2026?
Services and Other Revenue −$532K (-10%); Product −$187K (-1%).